Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

Mazyar Shadman, Associate Professor of Medical Oncology at Fred Hutch Cancer Center, shared on X about a paper titled “Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial” published on Blood.

Authors: Moritz Fürstenau, Adam Giza, Jonathan Weiss, Fanni Kleinert, Sandra Robrecht, Fabian Franzen, Janina Stumpf, Petra Langerbeins, Othman Al-Sawaf, Florian Simon, Anna-Maria Fink, Christof Schneider, Eugen Tausch, Johannes Schetelig, Peter Dreger, Sebastian Böttcher, Kirsten Fischer, Karl-Anton Kreuzer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek, Paula Cramer.

“Interesting data on AVO in relapsed or refractory CLL:

Our investigator initiated trial at Fred Hutch Cancer Center is currently activity enrolling.

AVENue-2: Fixed-duration AV for 2 years in patients with r/r CLL.”

Source: Mazyar Shadman/X